Last close As at 05/08/2026
—
— 0.00 (0.00%)
Market capitalisation
—
Evolva Holding
Written by
Evolva Holding |
Positive stevia newsflow |
Stevia update |
Food & beverages |
7 June 2016 |
Share price performance
Business description
Next events
Analysts
Evolva Holding is a research client of Edison Investment Research Limited |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Evolva has received two important pieces of good news: first, on 26 May it was granted a pivotal patent for the commercial production of fermentation-derived steviol glycosides, which is key to the expansion of stevia and demonstrated that Evolva is ahead of the competition. Second, on 1 June it was issued with a US FDA GRAS no objection letter for EverSweet. This news should serve as a reminder that EverSweet remains a key part of the Evolva investment case.
Year end |
Revenue (CHFm) |
PBT* |
EPS* |
DPS |
P/E |
Yield |
12/15 |
13.4 |
(32.1) |
(8.0) |
0.0 |
N/A |
N/A |
12/16e |
12.8 |
(34.7) |
(8.7) |
0.0 |
N/A |
N/A |
12/17e |
20.8 |
(34.9) |
(8.8) |
0.0 |
N/A |
N/A |
12/18e |
35.2 |
(28.2) |
(7.1) |
0.0 |
N/A |
N/A |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
Ahead of the competition
On 26 May Evolva announced it had been granted a European patent which is key to the commercial expansion of stevia sweeteners. The news allayed fears in the market that Evolva was lagging its competitors in terms of technology and the protection of its stevia intellectual property (IP), and in fact demonstrated that it is ahead of the competition. Separately, we note that on 1 June US Customs and Border Protection (CBP) issued a detention order on stevia produced by PureCircle in China based on information that forced labour is involved. This has been disputed by PureCircle, which is working to have its shipments released. While we cannot attempt to comment on whether or not forced labour is involved, this highlights the issue that the current methods of stevia production (directly from the stevia leaf) rely on complex supply chains which are hard to trace. Evolva’s fermentation method will simplify the supply chain and improve transparency, which should be of significant interest to the food and beverage manufacturers.
US FDA no objection letter
On 1 June the US Food and Drug Administration (FDA) issued a GRAS (generally recognized as safe) no objection letter for EverSweet, thus qualifying it for use in food and beverages. Obtaining GRAS status means that EverSweet can be treated as a normal food substance and does not require further tests to demonstrate its safety. Once Cargill and Evolva have addressed the current issues with production costs, which have not yet reached a competitive level, we believe there will be no further barriers to launch. We still forecast launch in 2018.
Valuation: Fair value of CHF1.14/share
Our fair value remains CHF1.14. Evolva is well capitalised with a cash position of CHF83.2m at end 2015. We forecast the company will have enough cash through to the end of FY17. However, if the option to enter into a JV with Cargill is exercised in 2017 and the previously issued capex guidance of c CHF30m is still valid, we expect Evolva will need to raise more cash by 2018.
Valuation
We value Evolva on a 25-year DCF basis. Our fair value is CHF1.14 (unchanged), or 40% potential upside. We are not revising our valuation at present, but note that the recent positive newsflow is certainly supportive of the investment case. We assume all product cash flows stop after 25 years and start to fade beyond 15 years; we also assume a WACC of 12.5% given we deem Evolva to be higher-than-average risk in relation to the consumer space. We illustrate a summary of our DCF valuation in Exhibit 1.
We do not expect any major catalysts in the short term, although clearly the recent stevia news is helpful and positive. We believe Evolva will continue to work on its current product suite and will continue to seek collaborations with new partners. Evolva’s prospects are mostly tied to the success of its stevia sweetener, EverSweet, although it is not fully dependent on it. Stevia accounts for c 40% of our valuation (after adjusting for tax and capex). The taste of EverSweet compared to existing stevia formulations continues to be a highly attractive proposition in our view, as Evolva’s product lacks the trademark bitter aftertaste, which hinders the use of traditional stevia at higher concentrations. However, the delay to the launch does increase the risk of a competing product being launched in the interim, although we are not aware of any imminent launches.
We note that although stevia accounts for a significant proportion of our valuation, Evolva also has other products. Nootkatone, which is being developed in collaboration with the US CDC (Center for Disease Control), has gained momentum and is now often mentioned as having potential for fighting off the Zika virus. It could also be effective against mosquitoes that transmit chikungunya, dengue and West Nile viruses, as well as repelling and killing the yellow fever mosquito and the black-legged tick, which transmits Lyme disease.
Evolva is well funded following the CHF57m capital raising in September 2015. We forecast the company will have enough cash through to the end of FY17. However, if the option to enter into a JV with Cargill is exercised in 2017 or early 2018, and the previously issued capex guidance of c CHF30m is still valid, our forecasts indicate that Evolva will need to raise more cash by 2018, so further rounds of capital raising remain a potential risk. The guidance issued at the time of the last capital raising was that capital expenditure of c CHF30m was required to convert and retrofit the existing Cargill fermentation facility in Blair, Nebraska. With the FY15 results, management confirmed that a contract-manufacturing route might be considered nearer the launch, but this would significantly reduce margins, and hence conversion of the facility in Blair, Nebraska remains the more likely option. We therefore believe a further round of capital raising is likely nearer the time of the EverSweet launch in 2018.
Exhibit 1: Summary of DCF valuation
Product |
Value (CHFm) |
Value per share (CHF) |
Notes |
Stevia royalties |
284.2 |
0.71 |
Launch date: 2018; peak sales: $600m; likelihood of success 80%; operating margin: 40%; profit share: 45%. |
Saffron royalties |
21.4 |
0.05 |
Launch date: 2018; peak sales: $100m; likelihood of success 60%; royalty: 10%. |
Resveratrol |
94.8 |
0.24 |
Launched; peak sales: $200m; likelihood of success 100%; margin: 40%. |
Vanilla royalties |
35.5 |
0.09 |
Launched; peak sales: $100m; likelihood of success 100%; royalty: 5%. |
Nootkatone |
59.9 |
0.15 |
Launched; peak sales: $100m; likelihood of success 75%*; margin: 40%. |
Valencene |
26.7 |
0.07 |
Launched; peak sales: $10m; likelihood of success 100%; margin: 40%. |
Santalol |
68.2 |
0.17 |
Launch date: 2017; peak sales: $50m; likelihood of success 60%; margin: 40%. |
Legacy products |
33.4 |
0.08 |
EV-077 for diabetic nephropathy, EV-035 antibiotic indications |
L'Oreal/Takasago revenues |
119.1 |
0.30 |
Launch date: 2019-21; number of products: 5; peak sales: $150m per product; likelihood of success: 50%; royalty: 8%. |
Other alliance royalties |
32.5 |
0.08 |
Royalties from alliances with Ajinomoto, BASF and Roquette; launch date: 2016-18; number of products: 3; peak sales: $150m per product; likelihood of success: 60%; royalty: 2%. |
Other revenues |
19.8 |
0.05 |
Only includes revenues from existing collaborations and grants. |
R&D and admin |
-267.3 |
-0.67 |
|
Tax |
-124.1 |
-0.31 |
|
Capex |
-33.0 |
-0.08 |
Includes investment of $30m for commercialisation of stevia with Cargill. |
Net cash |
83.2 |
0.21 |
Net cash at FY15 |
Total |
454.3 |
1.14 |
|
Source: Edison Investment Research. Note WACC = 12.5%. *There is no developmental risk associated with Nootkatone, but we have applied a risk adjustment due to uncertainty about the use of the product as an insect repellent.
Exhibit 2: Financial summary
CHF'000s |
2014 |
2015 |
2016e |
2017e |
2018e |
||
Year end 31 December |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
||
PROFIT & LOSS |
|||||||
Revenue |
|
|
10,744 |
13,364 |
12,772 |
20,835 |
35,210 |
Cost of Sales |
0 |
0 |
(1,411) |
(5,167) |
(12,069) |
||
Gross Profit |
10,744 |
13,364 |
11,361 |
15,668 |
23,141 |
||
EBITDA |
|
|
(19,405) |
(30,305) |
(33,808) |
(30,852) |
(24,635) |
Operating Profit (before GW and except.) |
(20,872) |
(31,947) |
(34,989) |
(32,139) |
(26,023) |
||
Intangible Amortisation |
(2,284) |
(3,779) |
(3,779) |
(3,779) |
(3,779) |
||
Exceptionals |
0 |
0 |
0 |
0 |
0 |
||
Operating Profit |
(23,156) |
(35,726) |
(38,768) |
(35,918) |
(29,803) |
||
Net Interest |
(357) |
(129) |
333 |
(2,714) |
(2,852) |
||
Other financial income |
57 |
0 |
0 |
0 |
647 |
||
Profit Before Tax (norm) |
|
|
(21,172) |
(32,076) |
(34,656) |
(34,852) |
(28,229) |
Profit Before Tax (FRS 3) |
|
|
(23,456) |
(35,855) |
(38,435) |
(38,632) |
(32,008) |
Tax |
1,613 |
4,067 |
0 |
0 |
0 |
||
Profit After Tax (norm) |
(19,069) |
(28,113) |
(34,656) |
(34,852) |
(28,229) |
||
Profit After Tax (FRS 3) |
(21,843) |
(31,788) |
(38,435) |
(38,632) |
(32,008) |
||
Average Number of Shares Outstanding (m) |
291.9 |
353.0 |
397.9 |
397.9 |
397.9 |
||
EPS - normalised (c) |
|
|
(6.4) |
(8.0) |
(8.7) |
(8.8) |
(7.1) |
EPS - FRS 3 (c) |
|
|
(7.3) |
(9.0) |
(9.7) |
(9.7) |
(8.0) |
Dividend per share (c) |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
||
Gross Margin (%) |
N/A |
N/A |
N/A |
N/A |
N/A |
||
EBITDA Margin (%) |
N/A |
N/A |
N/A |
N/A |
N/A |
||
Operating Margin (before GW and except.) (%) |
N/A |
N/A |
N/A |
N/A |
N/A |
||
BALANCE SHEET |
|||||||
Fixed Assets |
|
|
149,742 |
143,457 |
140,437 |
142,387 |
149,317 |
Intangible Assets |
136,111 |
131,940 |
128,161 |
124,381 |
120,602 |
||
Tangible Assets |
10,484 |
8,431 |
9,190 |
9,920 |
10,629 |
||
Other fixed assets |
3,147 |
3,086 |
3,086 |
8,086 |
18,086 |
||
Current Assets |
|
|
62,870 |
88,780 |
76,469 |
38,735 |
2,626 |
Stocks |
313 |
2,217 |
1,547 |
2,831 |
3,968 |
||
Debtors |
1,510 |
2,785 |
2,799 |
3,425 |
5,788 |
||
Cash |
60,713 |
83,228 |
71,573 |
31,929 |
(7,680) |
||
Other current assets |
334 |
550 |
550 |
550 |
550 |
||
Current Liabilities |
|
|
(13,460) |
(7,385) |
(7,700) |
(7,759) |
(7,798) |
Creditors |
(2,408) |
(1,182) |
(1,497) |
(1,557) |
(1,596) |
||
Short term borrowings |
(3,522) |
0 |
0 |
0 |
0 |
||
Finance lease obligations |
(354) |
(969) |
(969) |
(969) |
(969) |
||
Other current liabilities |
(7,176) |
(5,234) |
(5,234) |
(5,234) |
(5,234) |
||
Long Term Liabilities |
|
|
(24,158) |
(21,437) |
(40,468) |
(39,499) |
(38,530) |
Long term borrowings |
0 |
0 |
(20,000) |
(20,000) |
(20,000) |
||
Finance lease obligations |
(3,904) |
(4,134) |
(3,165) |
(2,196) |
(1,228) |
||
Other long term liabilities |
(20,254) |
(17,303) |
(17,303) |
(17,303) |
(17,303) |
||
Net Assets |
|
|
174,994 |
203,416 |
168,738 |
133,864 |
105,614 |
CASH FLOW |
|||||||
Operating Cash Flow |
|
|
(19,437) |
(31,353) |
(29,080) |
(28,945) |
(23,691) |
Net Interest |
(361) |
(376) |
333 |
(2,714) |
(2,852) |
||
Tax |
0 |
0 |
0 |
0 |
0 |
||
Capex |
(1,201) |
(1,865) |
(1,939) |
(2,017) |
(2,097) |
||
Acquisitions/disposals |
418 |
3,278 |
0 |
0 |
0 |
||
Financing |
56,776 |
59,956 |
0 |
0 |
0 |
||
Dividends |
0 |
0 |
0 |
0 |
0 |
||
Other cash flow |
(4,614) |
(3,975) |
(969) |
(5,969) |
(10,969) |
||
Net Cash Flow |
31,582 |
25,666 |
(31,655) |
(39,644) |
(39,609) |
||
Opening net debt/(cash) |
|
|
(25,633) |
(57,191) |
(83,188) |
(51,533) |
(11,889) |
HP finance leases initiated |
0 |
0 |
0 |
0 |
0 |
||
Other |
(25) |
331 |
0 |
0 |
0 |
||
Closing net debt/(cash) |
|
|
(57,191) |
(83,188) |
(51,533) |
(11,889) |
27,720 |
Source: Edison Investment Research, company data
Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com DISCLAIMER
|
[Grab your reader’s attention with a great quote from the document or use this space to emphasize a key point. To place this text box anywhere on the page, just drag it.]